- Market Capitalization, $K 46,133
- Shares Outstanding, K 12,302
- Annual Sales, $ 6,690 K
- Annual Income, $ -2,340 K
- 60-Month Beta -0.72
- Price/Sales 4.91
- Price/Cash Flow N/A
- Price/Book 4.03
|Period||Period Low||Period High||Performance|
| || |
-0.15 (-3.85%)since 07/02/21
| || |
-0.91 (-19.53%)since 04/30/21
| || |
-5.36 (-58.84%)since 07/31/20
an investor conference themed around investor education and advocacy begins next week, July 13 - 15, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period...
Biomerica Inc. (NASDAQ: BMRA) today announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica's new and proprietary...
-- IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% (approximately 20 million patients)
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced that it will be participating in two upcoming investor conferences: the Truist Life Sciences Series and LD...
The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor...
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, LODE, ONTX, PLTR, and BMRA.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NERV, FUBO, LHDX, BMRA, and LODE.
-- Less invasive nasal swab taken from front opening of the nose is more comfortable for patients
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced its fiscal third quarter 2021 financial results for the three months ended February 28, 2021.
-- Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021